Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics Q1 net loss narrows to $9.5 million on $12.6 million revenue

Positive Impact 3 of 5 earnings Written later

Xilio Therapeutics reported first quarter 2026 results, with collaboration and license revenue of $12.6 million, up from $2.9 million a year earlier, and a net loss of $9.5 million, down from $13.3 million. Net loss per share improved to $0.58 from $2.49, and the company said its cash runway now extends into early 2028.

Key points

  • Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, versus $2.9 million a year earlier, mainly from AbbVie and Gilead agreements.
  • R&D expenses rose to $19.8 million from $8.3 million, while G&A expenses fell to $6.9 million from $8.5 million.
  • Cash and cash equivalents were $150.3 million at March 31, 2026, versus $137.5 million at December 31, 2025, after $37.3 million in net proceeds from a February 2026 follow-on offering.
  • Xilio achieved a $6.0 million development milestone under the AbbVie collaboration in the second quarter of 2026 and plans to submit an XTX501 IND application in mid-2026.

The filing

CompanyXilio Therapeutics, Inc. (XLO)
Form8-K, current report
Filed with the SECMay 12, 2026, 7:35 AM ET
Accession number0001193125-26-218194

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.